Market Cap 405.51M
Revenue (ttm) 1.38M
Net Income (ttm) -83.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,071.01%
Debt to Equity Ratio 0.00
Volume 1,867,600
Avg Vol 3,407,590
Day's Range N/A - N/A
Shares Out 1.59B
Stochastic %K 28%
Beta -0.86
Analysts Strong Buy
Price Target $2.00

Company Profile

Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inop...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 497 9024
Address:
4800 Montgomery Lane, Suite 800, Bethesda, United States
Rainwater013
Rainwater013 Mar. 10 at 2:49 PM
$NWBO - 🤙
0 · Reply
Cocacola1971
Cocacola1971 Mar. 10 at 2:34 PM
$NWBO I think it might be Tuesday!! 🤪🤪🤪🤪🤪🤪
0 · Reply
pepinjax
pepinjax Mar. 10 at 2:28 PM
$NWBO hang on everyone!!
1 · Reply
archetypal
archetypal Mar. 10 at 2:10 PM
$NWBO This!!!
1 · Reply
Twister8
Twister8 Mar. 10 at 2:05 PM
$NWBO easy $$$ dilution scheme...
0 · Reply
robtown
robtown Mar. 10 at 1:54 PM
$NWBO I won’t eat again until approval… Or tomorrow dinner.
1 · Reply
Twister8
Twister8 Mar. 10 at 1:46 PM
$NWBO DCVax-L has been readily available to patients in the UK for the last several years, go fund me isn't investable.
1 · Reply
DeepThought
DeepThought Mar. 10 at 1:45 PM
$NWBO Once!
0 · Reply
Bajamike
Bajamike Mar. 10 at 1:40 PM
0 · Reply
Twister8
Twister8 Mar. 10 at 1:39 PM
$NWBO Is Dcvax-L even being used in Switzerland today? asking for a friend...
1 · Reply
Latest News on NWBO
No data available.
Rainwater013
Rainwater013 Mar. 10 at 2:49 PM
$NWBO - 🤙
0 · Reply
Cocacola1971
Cocacola1971 Mar. 10 at 2:34 PM
$NWBO I think it might be Tuesday!! 🤪🤪🤪🤪🤪🤪
0 · Reply
pepinjax
pepinjax Mar. 10 at 2:28 PM
$NWBO hang on everyone!!
1 · Reply
archetypal
archetypal Mar. 10 at 2:10 PM
$NWBO This!!!
1 · Reply
Twister8
Twister8 Mar. 10 at 2:05 PM
$NWBO easy $$$ dilution scheme...
0 · Reply
robtown
robtown Mar. 10 at 1:54 PM
$NWBO I won’t eat again until approval… Or tomorrow dinner.
1 · Reply
Twister8
Twister8 Mar. 10 at 1:46 PM
$NWBO DCVax-L has been readily available to patients in the UK for the last several years, go fund me isn't investable.
1 · Reply
DeepThought
DeepThought Mar. 10 at 1:45 PM
$NWBO Once!
0 · Reply
Bajamike
Bajamike Mar. 10 at 1:40 PM
0 · Reply
Twister8
Twister8 Mar. 10 at 1:39 PM
$NWBO Is Dcvax-L even being used in Switzerland today? asking for a friend...
1 · Reply
Twister8
Twister8 Mar. 10 at 1:38 PM
$NWBO going decades of the shitshow charade: “We are delighted to be the first company to reach the market with a personalized therapeutic vaccine for brain cancers, which carry a very bleak prognosis for patients today,” says Alton Boynton, Ph.D., president and CEO of Northwest Biotherapeutics. “Switzerland is an attractive place to begin commercialization due to its highly respected regulatory oversight and its growing experience with cellular therapies. Switzerland is also increasingly noted for medical tourism, and is easily accessible for many medical tourists.” In clinical trials, both newly diagnosed and recurrent brain cancer patients treated with DCVax-Brain had more than double the survival time of patients who did not receive the therapeutic, according to NWBT. In addition, unlike chemotherapy, the vaccine does not cause any debilitating side effects, the company adds. https://www.genengnews.com/news/nwbts-brain-cancer-vaccine-approved-in-switzerland/
0 · Reply
bernardkeogh
bernardkeogh Mar. 10 at 1:34 PM
0 · Reply
DeepThought
DeepThought Mar. 10 at 1:31 PM
$NWBO Advent Bioservices has received a full UK Manufacturing Authorisation (UK MIA 54923) for Human Medicinal Products, covering the commercial production of cell‑based therapies containing living cells. The licence includes: - Aseptic manufacturing capabilities - Authorisation for cellular and biological medicinal products - Qualified Person batch certification - Sterility and non‑sterility microbiological QC - Biological QC testing - Secondary packaging for commercial distribution This authorisation confirms that Advent’s Sawston facility is now fully approved for the commercial manufacture and release of advanced cell‑based therapeutics, removing one of the final regulatory barriers ahead of product approval and market launch.
3 · Reply
Jeff226
Jeff226 Mar. 10 at 1:24 PM
0 · Reply
Twister8
Twister8 Mar. 10 at 1:22 PM
$NWBO breadcrumb? Or a meatloaf sandwich?= https://www.genengnews.com/news/nwbts-brain-cancer-vaccine-approved-in-switzerland/
1 · Reply
Twister8
Twister8 Mar. 10 at 1:19 PM
$NWBO cult staying busy, keep at it, it’s up to .23c
1 · Reply
Zorch305
Zorch305 Mar. 10 at 1:14 PM
0 · Reply
Bullzballs
Bullzballs Mar. 10 at 1:10 PM
$NWBO I ask this question over and over and never get a response because there is none. I’ll ask it again. Please list all of the valid reasons to own this company
1 · Reply
DeepThought
DeepThought Mar. 10 at 1:08 PM
$NWBO I love breadcrumbs!
0 · Reply
BlastoiseShell
BlastoiseShell Mar. 10 at 1:07 PM
0 · Reply
Twister8
Twister8 Mar. 10 at 12:59 PM
$NWBO .23c can buy you some breadcrumbs…
1 · Reply
Matthewleo
Matthewleo Mar. 10 at 12:58 PM
0 · Reply